Novartis looks to manufacturing investment to drive down cost of siRNA drug

Novartis looks to manufacturing investment to drive down cost of siRNA drug

Source: 
Biopharma Reporter
snippet: 

Novartis has outlined plans to drive down the cost of producing its siRNA therapy, Leqvio, to support use in larger patient populations.